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Abstract Osteosarcoma is the most common primary bone cancer. It can be cured by
aggressive surgery and chemotherapy, but outcomes for metastatic or chemoresistant
disease remain dismal. Cancer sequencing studies have shown that the p53 pathway is
dysregulated in nearly every case, often by translocation; however, no studies of
osteosarcoma evolution or intratumor heterogeneity have been done to date. We
studied a patient with chemoresistant, metastatic disease over the course of 3 years. We
performed exome sequencing on germline DNA and DNA collected from tumor at three
separate time points. We compared variant calls and variant allele frequencies between
different samples. We identified subclonal mutations in several different genes in the
primary tumor sample and found that one particular subclone dominated subsequent
tumor samples at relapse. This clone was marked by a novel TP53-KPNA3 translocation
and loss of the opposite-strand wild-type TP53 allele. Future research must focus on the
functional significance of such clones and strategies to eliminate them.
[Supplemental material is available for this article.]
INTRODUCTION
Osteosarcoma is the most common primary bone cancer and primarily affects adolescents
and young adults (Mirabello et al. 2009). Anatomically, osteosarcomamost commonly affects
metaphyseal regions of the long bones (distal femur, proximal tibia, and proximal humerus).
Peak incidence occurs in adolescence and is associated with the adolescent growth spurt.
Aggressive surgery alone cures a fraction of affected patients. With the addition of neoadju-
vant chemotherapy with methotrexate, doxorubicin, and cisplatin, patients with nonmeta-
static disease at diagnosis currently have >70% long-term relapse-free survival (Mirabello
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therapeutic backbone, outcomes have not improved in the last three decades. Additionally,
patients with metastatic or relapsed disease continue to have dismal outcomes. As such,
identifying and targeting the biological drivers of metastatic and relapsed osteosarcoma re-
mains important in developing further improvements in therapy.
Osteosarcoma is linked to germline predisposition syndromes, most strongly hereditary
retinoblastoma (Hansen et al. 1985) and Li–Fraumeni syndrome (McIntyre et al. 1994). In ad-
dition, osteosarcoma predisposition has also been linked to germline mutations in RECQ
helicases, which causes Rothmund–Thomson syndrome (Kitao et al. 1999), and SQSTM1,
which predisposes to Paget’s disease of the bone (Laurin et al. 2002). More recently, ge-
nome-wide association studies have identified two risk loci near the GRM4 locus (Savage
et al. 2013). The only known environmental risk factor for developing osteosarcoma is expo-
sure to ionizing radiation.
A recent next-generation sequencing study of 34 primary pediatric osteosarcoma sam-
ples identified recurrent somatic mutations impairing p53 activity in nearly every sample
(Chen et al. 2014). The most striking mutations are translocations involving the TP53 gene
itself, particularly translocations involving the first intron. Such a rearrangement has even
been reported in the germline of one family with clinical Li–Fraumeni syndrome but without
mutation in the TP53 coding sequence (Ribi et al. 2015). Other genomic aberrations affect-
ing the p53 pathway include genomic loss of TP53 and modification of the MDM2 locus.
Recurrent somatic mutations were also found in RB1, ATRX, andDLG2. Another next-gener-
ation sequencing study also identified frequent copy number changes affecting genes in the
PI3K–mTOR pathway (Perry et al. 2014). However, none of these studies investigated geno-
mic drivers of chemoresistance.
Genomically, osteosarcoma may be more similar to adult-type cancers than other solid
tumors that affect young people. Unlike most pediatric cancers, osteosarcoma displays a
high rate of somatic mutation and even displays foci of kataegis, a specific type of localized
hypermutation previously identified in breast (Nik-Zainal et al. 2012), pancreatic, lung, and
other types of cancer (Alexandrov et al. 2013), but not previously identified in other pediatric
cancers. In addition, unlike most other pediatric cancer subtypes that respond well to multi-
agent chemotherapy, osteosarcoma remains primarily a surgical disease where grossly unre-
sectable disease is incurable with chemotherapy. In many adult cancer types, including lung
(de Bruin et al. 2014; Zhang et al. 2014), kidney (Gerlinger et al. 2012), and prostate cancer
(Gundem et al. 2015; Hong et al. 2015), deep sequencing has been used to study dynamics
of intratumor heterogeneity and to understand how these cancers change as they metasta-
size and develop chemoresistance. In some cases, a small fraction of the tumor already har-
boring a resistance-conferring mutation at diagnosis can become the dominant clone at the
time of relapse. In other cases, under the selective pressure of chemotherapy, acquisition of
new mutations drives the relapse clone (Ding et al. 2012). Occasionally, polyclonal seeding
can lead to metastasis and resistance (Gundem et al. 2015).
Herein, we describe genetic changes detected in longitudinally collected samples from
an aggressive, multiply relapsed metastatic osteosarcoma patient. These samples were tak-
en over the course of several years and through multiple courses of therapy. We performed
whole-exome sequencing from formalin-fixed, paraffin-embedded (FFPE) tumor samples to
study the evolution of this cancer during this time. Single-nucleotide variants (SNVs), inser-
tions or deletions (indels), and structural variants (SVs) were called. Strikingly, we identified a
novel translocation involving TP53 that accumulated in frequency over time. Unlike previous-
ly reported translocations, this one affected the 3′ untranslated region (3′ UTR) of TP53, re-
vealing a novel mechanism for dysregulating p53. Together, these results give fresh insight
into the genetic changes that occur as an osteosarcoma evolves, relapses, and metastasizes.
To our knowledge, no other study has investigated the subclonal dynamics of osteosarcoma
from diagnosis to death from multiple relapses.
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RESULTS
Clinical Presentation and Family History
The patient was a 25-yr-old man diagnosed with conventional, osteoblastic-type high-grade
osteosarcoma of the right fibula (Fig. 1). He received two rounds of preoperative chemother-
apy with cisplatin and doxorubicin before his primary tumor resection and received twomore
rounds postoperatively. However, 8 months after finishing chemotherapy, he was found to
have tumor recurrences in his fibula and lung. After two rounds of salvage chemotherapy
with methotrexate, ifosfamide, and etoposide, a secondary resection was performed. He
continued to receive chemotherapy, with ifosfamide, etoposide, and cisplatin. Nevertheless,
he continued to develop more metastatic disease in his lungs, axilla, scapula, and chest wall,
and a tertiary tumor sample was taken at this time that continued to show viable tumor.
Despite further attempts at salvagewith docetaxel, gemcitabine, and radiation, he ultimately
died of his disease.
Genomic Analyses
Germline tissue (blood) and primary, secondary, and tertiary tumor samples were submitted
for whole-exome sequencing. Alignment statistics are shown in Supplemental Table S1.
More than 45 million reads were obtained from each sample, and 95% of these were
mapped. This resulted in mean coverage depth of 40×–57× across all targeted regions.
Detection of Nonsynonymous Variants
In all, there were a total of 118 nonsynonymous variants in the primary tumor sample, 191
variants in the secondary tumor sample, and 290 variants in the tertiary tumor sample
(Fig. 2). A large number of the variants overlapped, especially between the secondary and
tertiary samples. The number of variants detected in each sample increased over time, which
may reflect accumulating mutations in response to chemotherapy. These variants are listed
in Supplemental Table S2. Despite the fact that mean coverage depth was only 40×–57×
and that the blood sample was processed differently than the tumor samples (which were






























Figure 1. Time line of events in the patient’s history, in months after diagnosis. Diagnosis of initial disease or
relapse displayed above the time line; interventions displayed below the time line. The patient was initially
treated with neoadjuvant and adjuvant chemotherapy sandwiched around a large resection of the primary
site of disease. This was followed by several relapses that were treated with the surgeries and chemotherapy
regimens as indicated. Please see text for further details. Chemotherapy regimens: AP, cisplatin and doxoru-
bicin (adriamycin); MEI, methotrexate, etoposide, and ifosfamide; IVP, ifosfamide, etoposide, and cisplatin;
GD, gemcitabine and docetaxel.
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FFPE), the vast majority of variants detected in germline tissue were also detected in the tu-
mor samples (Supplemental Fig. S1).
In addition, indels were detected using Pindel (Supplemental Table S3), and copy
number variation was computed using ExomeCNV (Supplemental Table S4; Supplemental
File S1).
Tumor Evolution
Next we used these variant calls to examine the evolutionary relationships among these sam-
ples by constructing a maximum parsimony phylogenetic tree and performing a principal
coordinate analysis in an unbiased manner. As shown in Figure 3A,B, these calculations
concurred with the time relationship between these samples. The primary tumor sample di-
verged from the germline (blood) sample, and the secondary and tertiary samples represent-
ed a further step in tumor evolution away from the primary sample.
In other tumor types, studies of intratumor heterogeneity have shown that chemothera-









Figure 2. Venn diagram of nonsynonymous variants identified in each sample. MuTect was used to call var-
iants in each sample that did not appear in the germline sequencing sample. See Supplemental Table S2 for all
variants.
BA C
Figure 3. Intersample relationships. (A) Phylogenetic tree. The Maximum Parsimony tree was obtained using
the Max-mini branch-and-bound algorithm. The branch lengths were calculated using the average pathway
method. Evolutionary analyses were conducted in MEGA6. (B) Principal coordinate analysis. The x- and y-
axes represent the first and second coordinates, respectively. In this case, the first and second principal coor-
dinates are genetic variation and somatic mutation, respectively. (C ) Heatmap displaying total root-mean-
square deviation of each sample’s variant allele frequencies from each other.
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diagnosis. However, this has not previously been studied in osteosarcoma. Thus, we next ex-
amined how these tumor samples related to one another to identify how subclonal popula-
tions shifted over the course of time. We calculated relationships between samples by
calculating the total root-mean-square deviation (RMSD) of each sample’s variant allele fre-
quencies (Fig. 3C).When comparedwith the reference genome, this again shows a clear pro-
gression from germline to primary, secondary, and tertiary tumor samples corresponding to
their relation in time. As these relationships are calculated from variant allele frequencies, this
implies the progression of a subclonal population in the primary tumor sample that becomes
the dominant clone in the tertiary sample.
Translocation Involving Chromosomes 13 and 17
Previous osteosarcoma sequencing studies have shown somatic events affecting the TP53
pathway in nearly every osteosarcoma sample studied; the most common TP53-related
events in osteosarcoma are translocations involving the TP53 gene itself (Chen et al. 2014;
Perry et al. 2014; Ribi et al. 2015). Thuswenext applied a soft-clipping-baseddetectionmeth-
od called sample heterogeneity estimation and assembly by reference (SHEAR) (Landman
et al. 2014) and a custom script we named “soft-clipping and realignment detects structural
variant frequency” (SCARF; see Methods for further detail) to identify fusion events in our
exome sequencing results (Supplemental Table S5). Strikingly, in all three tumor specimens,
we identified a t(13;17) translocation that fuses the 3′ UTR of TP53 to the first intron of KPNA3
(Fig. 4A; Supplemental File S2). Because this translocation involves an intron, our standard
exome-sequencing analysis pipeline did not detect it. Most translocations in osteosarcoma
involve the first intronofTP53; translocations involving the 3′ UTRofTP53 havenot previously
been reported.
To validate this finding, we performed Sanger sequencing on the three tumor samples.
We sequenced an amplicon produced with one primer aligning to Chromosome 13 and a
second to Chromosome 17 (Fig. 4B). We were unable to amplify the translocation from















Figure 4. TP53-KPNA3 translocation. (A) A schematic showing translocation between the last exon of TP53
and the first intron of KPNA3 as identified by whole-exome sequencing. The genomic coordinates are based
on hg19. (B) Sanger sequencing validation of the translocation breakpoint in secondary and tertiary tumor
samples.
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the primary tumor sample, but sequencing from the secondary and tertiary tumor samples
showed the translocation breakpoint concurring with the exome sequencing.
When we examined the frequency of reads supporting this translocation in our three tu-
mor samples, we noticed a striking accumulation of these reads in later tumor samples. The
ratio of reads supporting the translocation to reads supporting the reference TP53 sequence
increased from 0:65 in the germline sample to 10:62, 42:2, and 45:4 in the primary, second-
ary, and tertiary samples, respectively (Fig. 5). The increasing proportion of reads supporting
the translocation again supports the hypothesis that this translocation marks a subclonal
population that was present in the primary tumor sample but became the dominant clone
in subsequent postchemotherapy samples.
The number of reads corresponding to the translocation may be an underestimate of the
actual predominance of the translocation, as exome-captured reads would be enriched for
sequences containing exonic TP53 sequences. In support of this, we did not detect any
reads aligning to the KPNA3 intron alone, unconjugated to the TP53 exon.
In other osteosarcomas, translocations involving TP53 usually co-occur with loss of the
wild-type allele (Chen et al. 2014). In our case, because so few of the reads align to the ref-
erence sequence, it appears that the predominant clone has also undergone loss of the wild-
type TP53 allele. Accordingly, fluorescence in situ hybridization (FISH) for TP53 in the
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Figure 5. Reads in each sample supporting the reference TP53 exon versus the TP53-KPNA3 translocation
breakpoint. Genomic coordinates based on hg19. Duplicates included.
TP53-KPNA3 translocation in resistant osteosarcoma
C O L D S P R I N G H A R B O R
Molecular Case Studies
Chen et al. 2016 Cold Spring Harb Mol Case Stud 2: a000992 6 of 12
secondary and tertiary tumor samples appeared to show loss of one copy of TP53 in many
cells (Supplemental Fig. S2).
Finally, to determine the effect of this translocation on TP53 protein levels, we performed
immunohistochemistry (IHC) for TP53 on samples from biopsy, primary, secondary, and ter-
tiary archival tumor samples (Supplemental Fig. S3). Therewas no detectable TP53 protein in
any of the four samples by IHC, implying that the translocation results in functional TP53 loss.
DISCUSSION
Unlike many other malignancies of childhood or young adulthood, osteosarcoma outcomes
have not improved for several decades (Mirabello et al. 2009). Although chemotherapy may
treatmicroscopic residual disease, grossly unresected disease rarely responds to chemother-
apy. The next breakthroughs in osteosarcoma therapy will need to overcome this intrinsic
chemoresistance. In other types of cancer, studies of cancer evolution have unveiled the tu-
mor to be polyclonal at diagnosis, but under the selective pressure of chemotherapy, one or
a few therapy-resistant clones emerge to cause relapse (Ding et al. 2012). In retrospect, the
mutations present in the relapse clone are often detectable from the initial tumor sample at a
subclonal level. For example, one study of prostate cancer found an enrichment of TP53mu-
tations in metastatic subclones (Hong et al. 2015).
Here, for the first time, we show a similar pattern in osteosarcoma. Next-generation se-
quencing efforts in osteosarcoma have revealed variations affecting TP53 and related genes
in nearly every case. In this study we identify a subclonal TP53 translocation in the initial tu-
mor sample that became the dominant clone in subsequent chemotherapy-resistant sam-
ples. These results suggest that although other mutations, such as those affecting the
PI3K–mTOR pathway (Perry et al. 2014; Grignani et al. 2015), may contribute to osteosarco-
ma pathogenesis, overcoming therapy resistance may require therapy directed at p53-defi-
cient osteosarcoma.
Genomic instability and p53 inactivation are hallmarks of many cancer types, but SVs in-
volving the TP53 locus have heretofore been limited to two cancer types: prostate cancer
and osteosarcoma. This led Chen et al. to speculate that in osteosarcoma, deletion or trans-
location of p53 may actually be a result of genomic instability rather than the driver event
(Chen et al. 2014). In our case, the TP53-KPNA3 translocation was present at only subclonal
frequency in the diagnostic specimen, which suggests that it was actually a late event in os-
teosarcoma formation.
The TP53-KPNA3 translocation described here was not the only genetic aberration to
accumulate in frequency over time. Several other variants of unclear significance also
accumulated in the dominant clone (Supplemental Table S2). Unlike TP53 translocations,
none of these SNVs is in genes previously reported to be recurrently mutated in osteosarco-
ma. Although we cannot exclude the possibility that these mutations also contribute to
the emergence of this subclone, the recurrence of TP53 translocations in other osteosarco-
mas suggests that the TP53 translocation is the key genomic feature of the dominant recur-
rent subclone.
To our knowledge, translocations involving the TP53 3′ UTR, such as the TP53-KPNA3
translocation we identify here, have not previously been characterized, in either osteosarco-
ma or any other type of cancer. However, this subclonal translocation was not detected by
our routine exome-sequencing analysis pipeline (detecting genomic variants present in
only coding regions). In fact, it required an algorithm using soft-clipped reads to accurately
detect and estimate frequencies of structural variations with precise breakpoints at the nucle-
otide level across these tumors. Similar translocations, involving noncoding regions such as
introns and 5′ or 3′ UTRs, have likely been missed in previous studies. Although FFPE tissues
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may produce false positives when calling SNVs because of C>T artifacts, they are not known
to produce false translocations. Current sequencing data and analysis pipelines may require
custommodification to include introns and intergenic regions and detect such translocations
in cancer-related genes from FFPE-based sequencing projects.
In osteosarcoma, translocation involving one allele of TP53 commonly co-occurs with
loss of the opposite allele, and this appears to be especially true in samples derived
from osteosarcoma metastases (Miller et al. 1990; Chen et al. 2014). Cancer cells deficient
for P53 are resistant to DNA damage–triggered apoptosis in response to chemotherapy
and radiation (Lowe et al. 1993, 1994). However, this cannot be rescued by exogenous ex-
pression of the TP53 open reading frame (ORF) alone (Breen et al. 2007), suggesting that
regulatory elements surrounding the endogenous TP53 locus are also required for the p53
response. In fact, several RNA-binding proteins (Rosenstierne et al. 2008), including HuR
(Mazan-Mamczarz et al. 2003), RNPC1 (Zhang et al. 2011), and Wig-1 (Vilborg et al.
2009), bind to conserved elements in the TP53 3′ UTR and are responsible for up-regulat-
ing expression in the setting of DNA damage. Alternatively, the loss of these regulatory el-
ements may affect transcript stability through cellular processes such as nonsense-
mediated decay. In addition a region of the 5′ UTR has been shown to base-pair with
the 3′ UTR, and this base-pairing is also required for the induction of p53 following DNA
damage (Chen and Kastan 2010). For these reasons, this translocation, which separates
the TP53 coding sequence from its 3′ UTR, in combination with loss of the wild-type allele,
is likely to result in a loss of a cell’s capacity to induce p53 in response to DNA damage
such as by standard chemotherapy. This may explain the emergence of this clone after
chemotherapy.
METHODS
Patient Samples and Whole-Exome Sequencing
Blood and tumor samples were taken from a patient treated at Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, Republic of Korea.
For the germline sequencing, DNA was extracted from blood using LaboPass Blood
Miniprep Kit (Cosmogenetech, Ltd.). For tumor samples, FFPE blocks with a preponderance
of tumor cells were decalcified, and DNA was extracted using RecoverAll Total Nucleic Acid
Isolation Kit (Thermo Fisher Scientific). Library preparation and exome capture were done us-
ing the SureSelect Library Prep Kit and the SureSelect Automated Hybridization Kit (Agilent
Technologies, Inc.). Whole-exome sequencing was performed on one lane of paired-end,
100-bp reads on Illumina HiSeq for each sample.
Quality control was performed using the NGS QC Toolkit 2.3.3 (Patel and Jain 2012).
Sequences were aligned to the hg19 reference genome using bwa-0.7.10 (Li and Durbin
2009). Duplicates were marked and discarded using Picard 1.34. Genome Analysis Toolkit
(GATK) 3.4 was used to recalibrate base quality score, perform local realignment around
indels, and perform pooled multisample genotyping (McKenna et al. 2010; DePristo et al.
2011). SNVs were identified usingMuTect 1.1.4 (Cibulskis et al. 2013); indels were identified
using Pindel 0.2.5 (Ye et al. 2009); and copy number aberrations were identified using
ExomeCNV 1.4 (Sathirapongsasuti et al. 2011).
Detection of SNVs at Subclonal Frequency
SNVs present at subclonal frequency were detected using SHEAR (Landman et al. 2014). The
relationship between samples was calculated by RMSD. The RMSD value between two
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where L is a set of all sequenced loci with read depth >10 and VAF(l,s) is the variant
(nonreference) allele frequency on the locus l of the sample s. The custom Perl script used
in the calculation is downloadable at https://github.com/compbioUTSW/RMSD_of_VAF
and is also available in the Supplemental Material (Supplemental File S3).
Detection of Structural Variants at Subclonal Frequency
Finally, we sought to detect novel SVs, including those present at subclonal frequency. To
detect SVs using our whole-exome sequencing, we ran SHEAR as above to detect and
estimate the frequency of structural variation within a heterogeneous individual tumor
(Landman et al. 2014). We found the subclonal TP53–KPNA3 fusion across primary, second-
ary, and tertiary tumors with different estimated frequencies. To further investigate the
TP53–KPNA3 fusion event with exact breakpoints at nucleotide precision and its frequencies
across tumors, we produced a custom script, which we have named “soft-clipping and re-
alignment detects structural variant frequency” (SCARF) (Supplemental File S4).
Our custom script takes advantage of soft-clipped reads—that is, reads in which one end
of a paired-end read is perfectly aligned, but the opposite end is partially aligned to a nearby
region. The unaligned, soft-clipped subsequences are usually ignored. We collected soft-
clipped sequences in which (a) the soft-clipping position was identical in at least two reads;
(b) the aligned portion of the subsequence covered at least 10 bases; and (c) the mismatch
ratio in the aligned portion was <0.1. The soft-clipped subsequences were then merged into
one contig and aligned to the reference genome using BLAT (BLAST-like alignment tool;
Kent 2002) to discover the translocation partner. The BLAT search required that the previous-
ly aligned portion of these soft-clipped reads not align to the translocation partner to ensure
uniqueness. Frequency of the translocation was estimated as the number of reads support-
ing the translocation divided by the total number of reads supporting the translocation or
mapping to a 200-bp window around the breakpoint from either partner in the translocation.
The script used to detect such SVs, along with a toy example for demonstration purposes, is
downloadable at https://github.com/compbioUTSW/SCARF (Supplemental File S4).
Sanger Sequencing
Validation of the t(13;17) translocation was performed using one primer mapping to
Chromosome 13 (CTGCATGTCAATCTACAATCACC) and one mapping to Chromosome
17 (GGCCCACTTCACCGTACTAA). The resulting 205-bp amplicon was gel-extracted and
sequenced from both ends by Sanger sequencing.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization for TP53 was performed using the Vysis LSI TP53/CEP 17
FISH probe kit (Abbott Molecular) following standard protocols.
p53 Immunohistochemistry
IHC for p53 (dilution 1:100, clone D07; Novocastra) was performed on FFPE archival
blocks following standard protocols using a Ventana automatic immunostainer (Ventana,
Benchmark).
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ADDITIONAL INFORMATION
Data Deposition and Access
Raw sequencing data have been uploaded to the European Genome-phenome Archive
(EGA; https://www.ebi.ac.uk/ega/home) under study accession EGAS00001001805, and
the t(13;17) translocation sequence has been submitted to GenBank (http://www.ncbi.nlm.
nih.gov/genbank/) under accession KX396266.
Ethics Statement
All sequencing was performed under the supervision and approval of the Institutional Review
Board (IRB) at Severance Hospital, Yonsei University College of Medicine, Republic of Korea,
according to the Declaration of Helsinki principles. Written informed consent was received
from the participant before performing this study.
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